New Therapeutic Strategies in Gliomas Treatment

Caruso, Gerardo; Caffo, Mariella; Raudino, Giuseppe; Alafaci, Concetta; Tomasello, Francesco

doi:10.5772/19820

Cited by 4 publications

(3 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiogenesis seem to represent the key ratelimiting step to evolution from a low-grade glioma, anatomically limited, to a high grade glioma, diffuse and anatomically and biologically uncontrolled. On the base of this pathophysiological consideration, antiangiogenic approach appears to be an important therapeutic target for malignant gliomas [55]. Future possible molecular target may be clusterin, eIF-4E (eukaryotic initiation factor-4E), integrins, metalloproteinases and other key molecules involved in invasion and angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

Antisense Molecular Therapy in Cerebral Gliomas

Caruso

2012

J. Anal. Oncol.

View full text Add to dashboard Cite

Despite innovative therapeutic strategies, the expectative of life in patients affected by cerebral gliomas remain dismal. Malignant gliomas represent a class of infiltrative and aggressive neoplasms that are generally resistant to multimodal approach. The efficacy of classical anti-cancer strategies is seriously limited by lack of specific therapies against malignant cells.Glial tumors seem to be able to create a favorable environment for the invasion of glioma cells in cerebral parenchyma when they combine with the extracellular matrix via cell surface receptors. Recent advances in molecular and tumor biology have lead to a new class of modern antitumoral agents. Antisense oligonucleotides are synthetic stretches of DNA which hybridize with specific mRNA strands. The specificity of hybridization makes antisense method an interesting strategy to selectively modulate the expression of genes involved in tumorigenesis. In this review, molecular targets, clinical and experimental studies about the use of antisense oligonucleotides in cerebral gliomas treatment are reported.

show abstract

Section: Discussionmentioning

confidence: 99%

Antisense Molecular Therapy in Cerebral Gliomas

Caruso

2012

J. Anal. Oncol.

View full text Add to dashboard Cite

show abstract

“…Non-surgical therapies have much more important roles in brain tumour treatment. A good understanding of the interactions between GBM growth and tumour microenvironment will be necessary for the design and evaluation of anti-tumour therapy [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Mathematical Modelling of a Brain Tumour Initiation and Early Development: A Coupled Model of Glioblastoma Growth, Pre-Existing Vessel Co-Option, Angiogenesis and Blood Perfusion

Cai

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

We propose a coupled mathematical modelling system to investigate glioblastoma growth in response to dynamic changes in chemical and haemodynamic microenvironments caused by pre-existing vessel co-option, remodelling, collapse and angiogenesis. A typical tree-like architecture network with different orders for vessel diameter is designed to model pre-existing vasculature in host tissue. The chemical substances including oxygen, vascular endothelial growth factor, extra-cellular matrix and matrix degradation enzymes are calculated based on the haemodynamic environment which is obtained by coupled modelling of intravascular blood flow with interstitial fluid flow. The haemodynamic changes, including vessel diameter and permeability, are introduced to reflect a series of pathological characteristics of abnormal tumour vessels including vessel dilation, leakage, angiogenesis, regression and collapse. Migrating cells are included as a new phenotype to describe the migration behaviour of malignant tumour cells. The simulation focuses on the avascular phase of tumour development and stops at an early phase of angiogenesis. The model is able to demonstrate the main features of glioblastoma growth in this phase such as the formation of pseudopalisades, cell migration along the host vessels, the pre-existing vasculature co-option, angiogenesis and remodelling. The model also enables us to examine the influence of initial conditions and local environment on the early phase of glioblastoma growth.

show abstract

“…The nanotechnology, combined with the most recent targeted therapies, may actually represent a revolution in the targeting, transport and delivering of chemotherapeutic agents [81], thus opening new ways for the treatment of these tumors.…”

Section: Chemotherapymentioning

confidence: 99%

Meningiomas’ Management: An Update of the Literature

Cossu¹,

Messerer²,

Parker³

et al. 2016

Neurooncology - Newer Developments

View full text Add to dashboard Cite

Meningiomas are the most common primary intracranial tumors in the adult population [1]. They are generally considered benign lesions but after the 2007 WHO classification, the proportion of atypical meningiomas has steeply increased. Surgery is considered the mainstay of the treatment and a complete resection is considered curative in WHO grade I meningiomas. The role of adjuvant treatments like radiotherapy (stereotactic radiosurgery or conventional external beam irradiation) and chemotherapy in more aggressive cases is still discussed, above all in WHO grade II meningiomas. We would like to expose the most important advances in meningiomas' management in accordance with the recent literature evidences.

show abstract

New Therapeutic Strategies in Gliomas Treatment

Cited by 4 publications

References 67 publications

Antisense Molecular Therapy in Cerebral Gliomas

Antisense Molecular Therapy in Cerebral Gliomas

Mathematical Modelling of a Brain Tumour Initiation and Early Development: A Coupled Model of Glioblastoma Growth, Pre-Existing Vessel Co-Option, Angiogenesis and Blood Perfusion

Meningiomas’ Management: An Update of the Literature

Contact Info

Product

Resources

About